基于天然化合物的纳米医学的进步以及在性结肠炎治疗中与肠道微生物群的相互作用
Jinlan Zhang1,2,3,4, Shuhui Sun1,2,3,4, Huan Chen1,2,3,4
1Drug Delivery Research Center, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Frontiers in pharmacology
|July 31, 2023
概括
通过调节肠道微生物群,天然纳米药物对性结肠炎 (UC) 具有前途. 这篇评论探讨了天然化合物,纳米配方及其与肠道细菌的相互作用,以有效地治疗UC.
科学领域:
- 胃肠病学 胃肠病学
- 纳米医学是一种纳米医学.
- 微生物学 微生物学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,影响大肠.
- 肠道微生物群对于UC的发病,进展和治疗结果至关重要.
- 自然活性分子及其纳米配方为UC提供了潜在的治疗策略.
研究的目的:
- 审查用于UC治疗的基于自然活性分子的纳米药物.
- 探索纳米药物与UC肠道微生物群之间的复杂相互作用.
- 阐明这些相互作用背后的生物学机制及其治疗含义.
主要方法:
- 对UC的自然化合物衍生的纳米药物研究的文献综述.
- 分析肠道微生物群和代谢物在UC中的作用.
- 研究纳米药物和肠道微生物群之间的双向相互作用.
主要成果:
- 纳米粒子可以调节肠道微生物群的组成和代谢概况.
- 肠道微生物群影响纳米药物的疗效和治疗效益.
- 自然产品衍生的纳米药物在调节与UC相关的肠道失调症方面显示出潜力.
结论:
- 基于自然活性分子的纳米药物代表了UC治疗的有希望的途径.
- 了解肠道微生物群与纳米药物的相互作用是优化治疗策略的关键.
- 需要进一步的研究来应对挑战,并推进UC治疗中纳米药物的疗效.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
355
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
355
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
500
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
500
Peptic Ulcer Disease IV: Management
110
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
110
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195


